Windtree Therapeutics Shares Outstanding History (WINT)
Windtree Therapeutics reported 256,396 shares outstanding at the end of fiscal 2024.
View full Windtree Therapeutics company overviewWindtree Therapeutics annual shares outstanding history
| Fiscal year | Period ended | Shares outstanding | Change | Growth |
|---|---|---|---|---|
| 2024 | 2024-12-31 | 256,396 | 249,732 | +3747.48% |
| 2023 | 2023-12-31 | 6,664 | 5,805.998 | +676.69% |
| 2022 | 2022-12-31 | 858.002 | 229.804 | +36.58% |
| 2021 | 2021-12-31 | 628.198 | 252.165 | +67.06% |
| 2020 | 2020-12-31 | 376.033 | 71.646 | +23.54% |
| 2019 | 2019-12-31 | 304.387 | 66.363 | +27.88% |
| 2018 | 2018-12-31 | 238.024 | 214.117 | +895.63% |
| 2017 | 2017-12-31 | 23.907 | 20.676 | +639.93% |
| 2016 | 2016-12-31 | 3.231 | 0.196 | +6.46% |
| 2015 | 2015-12-31 | 3.035 | 0.771 | +34.04% |
| 2014 | 2014-12-31 | 2.264 | 0.025 | +1.12% |
| 2013 | 2013-12-31 | 2.239 | 1.084 | +93.89% |
| 2012 | 2012-12-31 | 1.155 | 0.505 | +77.58% |
| 2011 | 2011-12-31 | 0.65 | 0.285 | +78.12% |
| 2010 | 2010-12-31 | 0.365 | — | — |
Windtree Therapeutics quarterly shares outstanding
| Fiscal quarter | Period ended | Shares outstanding | Change | YoY change |
|---|---|---|---|---|
| Q3 2025 | 2025-09-30 | 33.6M | 33.6M | +71854748.77% |
| Q2 2025 | 2025-06-30 | 9.2M | 9.2M | +78019.71% |
| Q1 2025 | 2025-03-31 | 3.6M | 3.6M | +34849884.32% |
| Q4 2024 | 2024-12-31 | 256,396 | 249,732 | +3747.48% |
| Q3 2024 | 2024-09-30 | 46.809 | −5,673.435 | −99.18% |
| Q2 2024 | 2024-06-30 | 11,838.18 | 6,117.937 | +106.95% |
| Q1 2024 | 2024-03-31 | 10.204 | −999.811 | −98.99% |
| Q4 2023 | 2023-12-31 | 6,664 | 5,805.998 | +676.69% |
| Q3 2023 | 2023-09-30 | 5,720.243 | 4,994.761 | +688.47% |
| Q2 2023 | 2023-06-30 | 5,720.243 | 5,066.773 | +775.36% |
| Q1 2023 | 2023-03-31 | 1,010.014 | 377.364 | +59.65% |
| Q4 2022 | 2022-12-31 | 858.002 | 229.804 | +36.58% |
| Q3 2022 | 2022-09-30 | 725.482 | 132.05 | +22.25% |
| Q2 2022 | 2022-06-30 | 653.47 | 60.038 | +10.12% |
| Q1 2022 | 2022-03-31 | 632.651 | 49.16 | +8.43% |
| Q4 2021 | 2021-12-31 | 628.198 | 252.165 | +67.06% |
| Q3 2021 | 2021-09-30 | 593.432 | 217.399 | +57.81% |
| Q2 2021 | 2021-06-30 | 593.432 | 218.572 | +58.31% |
| Q1 2021 | 2021-03-31 | 583.49 | 279.104 | +91.69% |
| Q4 2020 | 2020-12-31 | 376.033 | 71.646 | +23.54% |
| Q3 2020 | 2020-09-30 | 376.033 | 137.597 | +57.71% |
| Q2 2020 | 2020-06-30 | 374.861 | 136.425 | +57.22% |
| Q1 2020 | 2020-03-31 | 304.387 | 65.951 | +27.66% |
| Q4 2019 | 2019-12-31 | 304.387 | 66.363 | +27.88% |
| Q3 2019 | 2019-09-30 | 238.436 | 210.517 | +754.02% |
| Q2 2019 | 2019-06-30 | 238.436 | 210.517 | +754.02% |
| Q1 2019 | 2019-03-31 | 238.436 | 214.529 | +897.36% |
| Q4 2018 | 2018-12-31 | 238.024 | 214.117 | +895.63% |
| Q3 2018 | 2018-09-30 | 27.919 | 22.163 | +385.01% |
| Q2 2018 | 2018-06-30 | 27.919 | 24.005 | +613.30% |
| Q1 2018 | 2018-03-31 | 23.907 | 20.355 | +573.04% |
| Q4 2017 | 2017-12-31 | 23.907 | 20.676 | +639.93% |
| Q3 2017 | 2017-09-30 | 5.756 | 2.617 | +83.37% |
| Q2 2017 | 2017-06-30 | 3.914 | 0.843 | +27.47% |
| Q1 2017 | 2017-03-31 | 3.552 | 0.504 | +16.52% |
| Q4 2016 | 2016-12-31 | 3.231 | 0.196 | +6.46% |
| Q3 2016 | 2016-09-30 | 3.139 | 0.175 | +5.89% |
| Q2 2016 | 2016-06-30 | 3.071 | 0.798 | +35.10% |
| Q1 2016 | 2016-03-31 | 3.048 | 0.78 | +34.38% |
| Q4 2015 | 2015-12-31 | 3.035 | 0.771 | +34.04% |
| Q3 2015 | 2015-09-30 | 2.965 | 0.707 | +31.32% |
| Q2 2015 | 2015-06-30 | 2.273 | 0.019 | +0.83% |
| Q1 2015 | 2015-03-31 | 2.268 | 0.018 | +0.82% |
| Q4 2014 | 2014-12-31 | 2.264 | 0.025 | +1.12% |
| Q3 2014 | 2014-09-30 | 2.258 | 0.805 | +55.37% |
| Q2 2014 | 2014-06-30 | 2.254 | 0.805 | +55.52% |
| Q1 2014 | 2014-03-31 | 2.25 | 1.092 | +94.34% |
| Q4 2013 | 2013-12-31 | 2.239 | 1.084 | +93.89% |
| Q3 2013 | 2013-09-30 | 1.453 | 0.302 | +26.21% |
| Q2 2013 | 2013-06-30 | 1.449 | 0.3 | +26.12% |
| Q1 2013 | 2013-03-31 | 1.158 | 0.011 | +0.93% |
| Q4 2012 | 2012-12-31 | 1.155 | 0.505 | +77.58% |
| Q3 2012 | 2012-09-30 | 1.151 | 0.508 | +79.09% |
| Q2 2012 | 2012-06-30 | 1.149 | 0.508 | +79.25% |
| Q1 2012 | 2012-03-31 | 1.147 | — | — |
| Q4 2011 | 2011-12-31 | 0.65 | 0.65 | +178016.18% |
| Q3 2011 | 2011-09-30 | 0.643 | — | — |
| Q2 2011 | 2011-06-30 | 0.641 | — | — |
| Q4 2010 | 2010-12-31 | 0 | — | — |
Windtree Therapeutics Share Buyback History
A share buyback, also called a stock repurchase, is when a company uses cash to buy its own shares. Windtree Therapeutics share buyback history shows the reported cash used for repurchases. Buybacks can reduce shares outstanding, but issuance, stock-based compensation, acquisitions, and stock splits can change the share count separately.
Windtree Therapeutics used $1.9M to repurchase common stock in fy 2024. Across the latest 2 reported fiscal years, total share repurchases were $1.9M. The latest reported quarter showed $4.2M of share repurchases.
| Fiscal year | Period ended | Share repurchases |
|---|---|---|
| 2024 | 2024-12-31 | $1.9M |
| 2023 | 2023-12-31 | $0 |
TickerStat uses SEC-reported cash payments for common-stock repurchases. The amounts describe capital returned through buybacks; they are not a forecast or a measure of the number of shares retired.
Windtree Therapeutics shares outstanding trends
Over the last five fiscal years, Windtree Therapeutics's shares outstanding moved from 304.387 to 256,396, a change of 256,091.613. The latest reported quarter, Q3 2025, shows 33.6M.
What shares outstanding means
Shares outstanding is the number of common shares held by investors at a reporting-period end. The count can change because of stock issuance, repurchases, conversions, acquisitions, or stock splits.
SEC-reported period-end shares
TickerStat displays period-end common shares from SEC filings and adjusts older values to the current share basis when a stock-split conversion ratio is reported directly or evidenced by a later filing’s restated historical share balance. After repeated reverse splits, an old period can represent less than one current-basis share; this is a split-adjusted equivalent, not a literal historical certificate count. Values remain as reported when no reliable split ratio is available. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Windtree Therapeutics source filings ↗